DRL, Cipla’s healthy outlook offsets Q4 slip, will help retain investor interest
Both companies managed operational efficiency through improved ebitda margins.
Synopsis
For DRL, the US business failed to generate growth compared to the previous year partly due to high base effect as well as price erosion. India sales grew 15% over the year-ago level, aided by sales from the acquired business of Wockhardt and new product launches.
ET Intelligence Group: Dr Reddy’s Labs (DRL) and Cipla, the two leading domestic pharmaceutical companies in Covid-19 treatment, did not live up to investors’ expectations when they announced their fourth quarter results last Friday. Overall sales of these companies in the quarter to March were lower, given the easing of the pandemic, than in the preceding quarters which were hit by the first wave of corona virus.
For DRL, the US business
